Integrity and quantity of salivary cell-free DNA as a potential molecular biomarker in oral cancer: A preliminary study
- PMID: 35416334
- PMCID: PMC9322526
- DOI: 10.1111/jop.13299
Integrity and quantity of salivary cell-free DNA as a potential molecular biomarker in oral cancer: A preliminary study
Abstract
Background: Differences in cell-free DNA (cfDNA) fragments have been described as a valuable tool to distinguish cancer patients from healthy individuals. We aim to investigate the concentration and integrity of cfDNA fragments in saliva from oral squamous cell carcinoma (OSCC) patients and healthy individuals in order to explore their value as diagnostic biomarkers.
Methods: Saliva samples were collected from a total of 34 subjects (19 OSCC patients and 15 healthy controls). The total concentration of salivary cfDNA (scfDNA) was determined using a fluorometry method and quantitative real-time polymerase chain reaction (qPCR). To evaluate the scfDNA quantity and integrity, qPCR targeting Arthobacter luteus (ALU) sequences at three amplicons of different lengths (60, 115, and 247 bp, respectively) was carried out. ScfDNA integrity indexes (ALU115/ALU60 and ALU247/ALU60) were calculated as the ratio between the absolute concentration of the longer amplicons 115 bp and 247 bp and the total scfDNA amount (amplicon 60 bp).
Results: The total scfDNA concentration (ALU60) was higher in OSCC than in healthy donors, but this trend was not statistically significant. The medians of scfDNA integrity indexes, ALU115/ALU60 and ALU247/ALU60, were significantly higher in OSCC, showing area under the curve values of 0.8211 and 0.7018, respectively.
Conclusion: Our preliminary results suggest that scfDNA integrity indexes (ALU115/ALU60 and ALU247/ALU60) have potential as noninvasive diagnostic biomarkers for OSCC.
Keywords: ALU repeat; DNA integrity; liquid biopsy; oral squamous cell carcinoma (OSCC); saliva; salivary cell-free DNA (scfDNA).
© 2022 The Authors. Journal of Oral Pathology & Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
R. López‐López reports other from Nasasbiotech, during the conduct of the study; grants and personal fees from Roche, grants and personal fees from Merck, personal fees from AstraZeneca, personal fees from Bayer, personal fees, and nonfinancial support from BMS, personal fees from Pharmamar, personal fees from Leo, outside the submitted work. The rest of the authors have nothing to disclose.
Figures



Similar articles
-
[Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].Zhonghua Zhong Liu Za Zhi. 2018 Dec 23;40(12):905-910. doi: 10.3760/cma.j.issn.0253-3766.2018.12.006. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 30605980 Chinese.
-
Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.Pathol Oncol Res. 2019 Jul;25(3):925-936. doi: 10.1007/s12253-017-0380-6. Epub 2018 Jan 28. Pathol Oncol Res. 2019. PMID: 29376201
-
Saliva-derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non-small cell lung cancer.Thorac Cancer. 2019 Oct;10(10):1973-1983. doi: 10.1111/1759-7714.13178. Epub 2019 Aug 23. Thorac Cancer. 2019. PMID: 31441578 Free PMC article.
-
Salivary RNA signatures in oral cancer detection.Anal Cell Pathol (Amst). 2014;2014:450629. doi: 10.1155/2014/450629. Epub 2014 Dec 10. Anal Cell Pathol (Amst). 2014. PMID: 25763326 Free PMC article. Review.
-
Salivary CCL20 Level as a Biomarker for Oral Squamous Cell Carcinoma.Cancer Genomics Proteomics. 2021 Mar-Apr;18(2):103-112. doi: 10.21873/cgp.20245. Cancer Genomics Proteomics. 2021. PMID: 33608307 Free PMC article. Review.
Cited by
-
A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection.Int J Mol Sci. 2023 May 10;24(10):8520. doi: 10.3390/ijms24108520. Int J Mol Sci. 2023. PMID: 37239866 Free PMC article.
-
Saliva-based cell-free DNA and cell-free mitochondrial DNA in head and neck cancers have promising screening and early detection role.J Oral Pathol Med. 2023 Jan;52(1):29-36. doi: 10.1111/jop.13392. Epub 2022 Dec 13. J Oral Pathol Med. 2023. PMID: 36459078 Free PMC article.
-
Liquid biopsies based on cell-free DNA as a potential biomarker in head and neck cancer.Jpn Dent Sci Rev. 2023 Dec;59:289-302. doi: 10.1016/j.jdsr.2023.08.004. Epub 2023 Aug 29. Jpn Dent Sci Rev. 2023. PMID: 37680614 Free PMC article. Review.
-
Liquid Biopsy in Head and Neck Cancer: Its Present State and Future Role in Africa.Cells. 2023 Nov 20;12(22):2663. doi: 10.3390/cells12222663. Cells. 2023. PMID: 37998398 Free PMC article. Review.
-
The Global Trends and Advances in Oral Microbiome Research on Oral Squamous Cell Carcinoma: A Systematic Review.Microorganisms. 2025 Feb 8;13(2):373. doi: 10.3390/microorganisms13020373. Microorganisms. 2025. PMID: 40005740 Free PMC article. Review.
References
-
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209‐249. - PubMed
-
- Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531‐548. - PubMed
-
- Wan JCM, Massie C, Garcia‐Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223‐238. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical